Harnessing anticancer drugs for the future fight against influenza

Sep 05, 2012
In search for novel antivirals, a total of 201 host-directed compounds were tested for their antiviral efficacy. Credit: FIMM / Oxana Denisova

Medical Systems Virology group at the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki, together with its national and international collaborators, developed a new cell screening method that can be used to identify potential anti-influenza drugs. The researchers were able to identify two novel compounds with anti-influenza activity, obatoclax and gemcitabine and prove the efficacy of a previously known drug saliphenylhalamide.

The study was recently accepted for publication in the and is now available online.

Influenza viruses cause significant human morbidity and mortality. To treat the infections, different virus-directed drugs have been developed. However, the currently available drugs are targeting and due to a high the influenza viruses quickly develop resistance to them. For that reason, next-generation antiviral drugs should be directed towards the host functions. The results of this study provide a foundation for development of next-generation antiviral drugs. Furthermore, these identified compounds can be used as chemical tools when studying the molecular mechanisms of virus-host interactions.

"An interesting aspect of this study is that the antiviral effects of obatoclax, saliphenylhalamide and gemcitabine, which all are either investigational or approved anticancer agents, are achieved at much lower concentrations than that needed to mediate cancer cell death" said the group leader Denis Kainov.

However, further research is still needed before these drugs can be clinically tested and applied in influenza infections.

This research project is a good example of repurposing of drugs, i.e. finding new applications for existing drugs and thus saving money and time on drug development.

"We anticipate that these types of drugs could in the future reinforce the therapeutic arsenal and address the needs of the society to control ", said Olli Kallioniemi, the Director of FIMM.

Explore further: Following a protein's travel inside cells is key to improving patient monitoring, drug development

More information: Denisova OV, Kakkola L, Feng L, Stenman J, Nagaraj A, Lampe J, Yadav B, Aittokallio T, Kaukinen P, Ahola T, Kuivanen S, Vapalahti O, Kantele A, Tynell J, Julkunen I, Kallio-Kokko H, Paavilainen H, Hukkanen V, Elliott RM, De Brabander JK, Saelens X and Kainov DE. Obatoclax, saliphenylhalamide and gemcitabine inhibit influenza A virus infection. Journal of Biological Chemistry, 2012 (online, doi:10.1074/jbc.M112.392142)

add to favorites email to friend print save as pdf

Related Stories

Study offers new information for flu fight

Jan 27, 2012

Influenza virus can rapidly evolve from one form to another, complicating the effectiveness of vaccines and anti-viral drugs used to treat it. By first understanding the complex host cell pathways that the flu uses for replication, ...

Fighting drug-resistant flu viruses

Jul 15, 2009

Amid reports that swine flu viruses are developing the ability to shrug off existing antiviral drugs, scientists in Japan are reporting a first-of-its kind discovery that could foster a new genre of antivirals ...

Recommended for you

The anti-inflammatory factory

Apr 22, 2014

Russian scientists, in collaboration with their colleagues from Pittsburgh University, have discovered how lipid mediators are produced. The relevant paper was published in Nature Chemistry. Lipid mediators are molecules that p ...

User comments : 0

More news stories

When things get glassy, molecules go fractal

Colorful church windows, beads on a necklace and many of our favorite plastics share something in common—they all belong to a state of matter known as glasses. School children learn the difference between ...

FCC to propose pay-for-priority Internet standards

The Federal Communications Commission is set to propose new open Internet rules that would allow content companies to pay for faster delivery over the so-called "last mile" connection to people's homes.

SK Hynix posts Q1 surge in net profit

South Korea's SK Hynix Inc said Thursday its first-quarter net profit surged nearly 350 percent from the previous year on a spike in sales of PC memory chips.